IRLAB Therapeutics

OMX: IRLABA

Market CapSEK1,950m

Last Close SEK37.75

Based in Scandinavia, IRLAB Therapeutics is focused on developing novel drugs for the treatment of neurodegenerative diseases utilising its ISP technology platform. Its two lead assets are in late-stage clinical trials for the symptomatic treatment of PD: mesdopetam (D3 antagonist) and pirepemat (PFC enhancer).

More IRLAB Therapeutics content >

Investment summary

IRLAB Therapeutics is focused on developing novel, potential first-in-class treatments for the symptoms of Parkinson’s disease (PD) and other central nervous system disorders. IRLAB’s proprietary ISP research platform is at the heart of its discovery engine and has been validated by the progress of its two lead assets, mesdopetam and pirepemat, which have novel mechanisms of action. Pirepemat is an oral prefrontal cortex enhancer currently in development for the treatment of impaired balance and falls in PD; a global Phase IIb study is expected to start shortly. Mesdopetam, an oral D3 antagonist, is currently in a global Phase IIb/III study for levodopa-induced dyskinesias and top-line data are expected in H222. A global licensing deal (worth up to $363m) for mesdopetam puts all future clinical development and commercialisation in the hands of partner Ipsen, enabling IRLAB to focus on its preclinical pipeline which consists of IRL942, IRL 757 and compounds from its P003 programme. IRLAB is well funded in the medium term.

Y/E Dec
Revenue (SEKm)
EBITDA (SEKm)
PBT (SEKm)
EPS (öre)
P/E (x)
P/CF (x)
2019A 0.4 (92.9) (95.1) (234.0) N/A N/A
2020A 0.4 (89.2) (91.4) (192.0) N/A N/A
2021E N/A N/A N/A N/A N/A N/A
2022E N/A N/A N/A N/A N/A N/A
Industry outlook

PD is characterised by a triad of cardinal motor symptoms, although non-motor symptoms are as debilitating and remain undertreated. Despite substantial efforts to develop disease-modifying approaches in PD, symptomatic treatment remains the mainstay.

Last updated on 26/05/2022
Content on IRLAB Therapeutics
IRLAB Therapeutics – Screening platform continues to bear fruit
Healthcare | research Flash note | 13 May 2022
Brain disease diagnosis with medical doctor seeing Magnetic Resonance Imaging (MRI) film diagnosing elderly ageing patient neurodegenerative illness problem for neurological medical treatment
IRLAB Therapeutics – Looking beyond mesdopetam
Healthcare | research Update | 30 March 2022
Brain disease diagnosis with medical doctor seeing Magnetic Resonance Imaging (MRI) film diagnosing elderly ageing patient neurodegenerative illness problem for neurological medical treatment
IRLAB Therapeutics – Pirepemat and platform potential come into focus
Healthcare | research Update | 28 February 2022
Brain disease diagnosis with medical doctor seeing Magnetic Resonance Imaging (MRI) film diagnosing elderly ageing patient neurodegenerative illness problem for neurological medical treatment
View more
Register to receive research on IRLAB Therapeutics as it is published
Share price graph
Balance sheet
Forecast net debt (SEKm) N/A
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 4.4 15.6 3.6
Relative* 10.2 24.9 17.0
52-week high/low SEK70.0/SEK29.4
*% relative to local index
Key management
Nicholas Waters CEO
Viktor Siewertz CFO